Medical Oncology

, Volume 25, Issue 3, pp 356–359

Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases

Authors

  • Murat Dincer
    • Department of Medical OncologyHacettepe University Institute of Oncology
    • Department of Medical OncologyHacettepe University Institute of Oncology
  • Hakan Harputluoglu
    • Department of Medical OncologyHacettepe University Institute of Oncology
  • Sercan Aksoy
    • Department of Medical OncologyHacettepe University Institute of Oncology
  • Mustafa Cengiz
    • Department of Radiation OncologyHacettepe University Institute of Oncology
  • Ibrahim Gullu
    • Department of Medical OncologyHacettepe University Institute of Oncology
Original Paper

DOI: 10.1007/s12032-008-9045-3

Cite this article as:
Dincer, M., Altundag, K., Harputluoglu, H. et al. Med Oncol (2008) 25: 356. doi:10.1007/s12032-008-9045-3

Abstract

Zoledronic acid (ZA) delays the onset or reduces the incidence of skeletal complications in breast cancer patients with bone metastases. However, there are few data on the long-term renal safety of ZA. We retrospectively evaluated 43 breast cancer patients with bone metastases who received ZA more than 24 months. The following parameters measured prior to first ZA use and after the last dose of ZA administration were compared: serum creatinine (SCr), blood urea nitrogen (BUN), alkaline phosphatase (ALP), calcium (Ca), and phosphorous (P). Forty-three breast cancer patients with documented bone metastases were evaluated. Median age at the start of treatment was 53 years (range 37–77). Median overall duration of ZA administration was 36 months (25–62). There were no statistically significant differences in the pre- and post-treatment levels of SCr, BUN, Ca and P. However, ALP levels after long-term ZA administration were decreased significantly (P < 0.05). More than 24 months of ZA administration did not adversely affect the renal function. ZA can be used safely in breast cancer patients with bone metastases beyond 2 years.

Keywords

Zoledronic acidRenal safetyBreast cancerBone metastases

Copyright information

© Humana Press Inc. 2008